HK Stock Market Move | LEPU BIO (02157) rises over 4% as CMG901 clinical study results selected for LBA and to be presented at a Presidential Symposium

LEPU BIO (02157) rose over 4%, up 3.56% as of press time, at HK$3.935, with a turnover of HK$11.9371 million. On the news front, LEPU BIO announced that at the European Society for Medical Oncology Annual Congress 2026 (2026 ESMO Congress): positive research results from the Phase III clinical trial of CMG901 for second-line and later-line (2L+) Claudin 18.2-positive advanced/metastatic gastroesophageal cancer (GEC) have been selected as a Late-Breaking Abstract (LBA) and will be presented as a preferred paper at a Presidential Symposium; positive results from the Phase I clinical study of MRG007 (a potential best-in-class CDH17-targeting antibody-drug conjugate (ADC) candidate for the treatment of colorectal cancer (CRC)) have been selected as an LBA and will be presented as a rapid oral presentation at the congress. Positive results from the European Phase II study of MRG003 in combination with HX008 for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) have been selected for a rapid oral presentation; and positive results from the Phase II study of MRG003 in combination with HX008 for the treatment of epidermal growth factor receptor-positive (EGFR-positive) unresectable anaplastic/poorly differentiated thyroid cancer have been selected for a rapid oral presentation.